SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Bio Technology General - BTGC -- Ignore unavailable to you. Want to Upgrade?


To: Jim Oravetz who wrote (1863)6/19/1999 7:09:00 PM
From: yosi s  Read Replies (1) | Respond to of 2028
 
"Hep-B is not a HUGE profit drug. It will contribute, but not all that
much (to propel the stock upward)."
If they get to market it in China, Korea and Japan. Very high incidence of B hepatitis. Adult market Plus neonates
ie every new born gets it.( Their is better priced and need less repeated shots.)
In NY state it is now required to be vaccinated with Hep B to get to first grade